Gene transfer using the mature form of VEGF-D reduces neointimal thickening through nitric oxide-dependent mechanism.
Gene transfer to the vessel wall using vascular endothelial growth factors (VEGFs) has shown therapeutic potential for the treatment of restenosis. In this study, we evaluated the effect of catheter-mediated adenoviral (Ad) gene transfer of the mature form of VEGF-D (VEGF-D(DeltaNDeltaC)) in balloon-denuded cholesterol-fed rabbit aorta. AdLacZ was used as a control. Transduced VEGF-D(DeltaNDeltaC) mRNA was detectable in the arterial wall with RT-PCR at 6, 14 and 28 days. Gene transfer efficiency as detected with X-gal staining 6 days after the AdLacZ transduction was 1.91 +/- 1.32% in intima. AdVEGF-D(DeltaNDeltaC) gene transfer led to 52% reduction in intima/media ratio (I/M) as compared to the AdLacZ controls at 14 days time point. At 6 days there were no differences in I/M, but the number of macrophages in the vessel wall was 85% lower in the AdVEGF-D(DeltaNDeltaC) group as compared to the controls. The therapeutic effect was no longer detectable 28 days after the gene transfer. The therapeutic effect of VEGF-D(DeltaNDeltaC) was nitric oxide (NO)-dependent as the feeding of NO synthase inhibitor, L-NAME, blocked the reduction in intimal thickening. It is concluded that AdVEGF-D(DeltaNDeltaC) gene transfer reduces intimal thickening and macrophage influx into the vessel wall in balloon-denuded rabbit aortas.
Rutanen
J
J
Department of Molecular Medicine, A.I. Virtanen Institute, University of Kuopio, Finland.
Turunen
A-M
AM
Teittinen
M
M
Rissanen
T T
TT
Heikura
T
T
Koponen
J K
JK
Gruchala
M
M
Inkala
M
M
Jauhiainen
S
S
Hiltunen
M O
MO
Turunen
M P
MP
Stacker
S A
SA
Achen
M G
MG
Ylä-Herttuala
S
S
D000256:Adenoviridae / Q000235:genetics*; D000818:Animals; D001011:Aorta; D001018:Aortic Diseases / Q000378:metabolism / Q000473:pathology / Q000628:therapy*; D002404:Catheterization; D003251:Constriction, Pathologic / Q000628:therapy; D015316:Genetic Therapy / Q000379:methods*; D005822:Genetic Vectors / Q000008:administration & dosage*; D009389:Neovascularization, Pathologic; D009569:Nitric Oxide / Q000378:metabolism; D011817:Rabbits; D012008:Recurrence; D020133:Reverse Transcriptase Polymerase Chain Reaction; D014161:Transduction, Genetic / Q000379:methods*; D017539:Tunica Intima / Q000378:metabolism / Q000473:pathology; D042643:Vascular Endothelial Growth Factor D / Q000235:genetics* / Q000378:metabolism
D042643:Vascular Endothelial Growth Factor D; D009569:Nitric Oxide